According to the JP Morgan Health Care presentation
No. of Potential customers targeted are according to my calculations are:
Total prevalence of OA in key markets are 72M + and growing.
81% unhappy with current treatment
Target uptake 10% of those unhappy with current treatment. (72M * .81) =
5.832 Million targeted customers
Pricing indicated US$2500 per year
Revenue: US$14,580,000,000
Is my maths wrong?
Valuation of PAR, page-2
-
- There are more pages in this discussion • 78 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
25.5¢ |
Change
-0.005(1.92%) |
Mkt cap ! $89.19M | |||
| Open | High | Low | Value | Volume |
| 27.0¢ | 27.0¢ | 25.5¢ | $261.4K | 990.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 9999 | 25.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 26.0¢ | 9445 | 1 |
View Market Depth
| Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
| PAR (ASX) Chart |